Evidence map›Paper›PMID 31850122›Full record

ReviewOpen access Macedonian journal of medical sciences2019

Clinical Applications of System Regulation Medicine.

Massimo Fioranelli, Alireza Sepehri, Maria Grazia Roccia, Cota Linda, Chiara Rossi, Amos Dawodo, Petar Vojvodic, Jacopo Lotti, Victoria Barygina, Aleksandra Vojvodic and 4 more

Open access · diamondAbstract readReview
In one paragraph

Review in Open access Macedonian journal of medical sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 0 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 4 countries.

Massimo FioranelliDepartment of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy.
Alireza SepehriDepartment of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy.
Maria Grazia RocciaDepartment of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy.
Cota LindaDepartment of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy.
Chiara RossiDepartment of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy.
Amos DawodoDepartment of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy.
Petar VojvodicClinic for Psychiatric Disorders "Dr. Laza Lazarevic", Belgrade, Serbia.
Jacopo LottiDepartment of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy.
Victoria BaryginaDepartment of Biomedical Experimental and Clinical Sciences, University of Florence, Florence, Italy.
Aleksandra VojvodicDepartment of Dermatology and Venereology, Military Medical Academy, Belgrade, Serbia.
Uwe WollinaDepartment of Dermatology and Allergology, Städtisches Klinikum Dresden, Dresden, Germany.
Michael TirantG. Marconi University, Rome, Italy.
Thuong Nguyen VanVietnam National Hospital of Dermatology and Venereology, Hanoi, Vietnam.
Torello LottiDepartment of Dermatology, University of G. Marconi, Rome, Italy.
Marconi University · ITKlinika za Psihijatrijske Bolesti Dr Laza Lazarević · RSMilitary Medical Academy · RSNational Hospital of Pediatrics · VNStädtisches Klinikum Dresden · DEUniversity of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing incidence and poor outcome of chronic non-communicable diseases in western population would require a paradigm shift in the treatments. Guidelines-based medical approaches continue to be the standard rule in clinical practice, although only less than 15% of them are based on high-quality research. For each person who benefits from the 10 best-selling drugs in the USA, a number between 4 and 25 has no one beneficial effect. The reductionist linear medicine method does not offer solutions in the non-manifest preclinical stage of the disease when it would still be possible to reverse the pathological progression and the axiom "a drug, a target, a symptom" are still inconclusive. Needs additional tools to address these challenges. System Medicine considers the disease as a dysregulation of the biological networks that changes throughout the evolution of the pathological process and with the comorbidities development. The strength of the networks indicates their ability to withstand dysregulations during the perturbation phases, returning to the state of stability. The treatment of dysregulated networks before the symptomatological manifestation emerges offers the possibility of treating and preventing pathologies in the preclinical phase and potentially reversing the pathological process, stopping it or preventing comorbidities. Furthermore, treating shared networks instead of individual phenotypic symptoms can reduce drug use, offering a solution to the problem of ineffective drug use.

Indexed as

Bioregulatory Systems MedicineNetworksPreclinical

Identifiers

PMID31850122
PMCPMC6910802
OpenAlexW2988907005

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.